


## Topoisomerase II $\alpha$ -IN-5

Cat. No.:	HY-152187
Molecular Formula:	C <sub>25</sub> H <sub>30</sub> N <sub>2</sub> O <sub>5</sub>
Molecular Weight:	438.52
Target:	Topoisomerase; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Topoisomerase II $\alpha$ -IN-5 is a topoisomerase II (topo II) $\alpha$ catalytic inhibitor. Topoisomerase II $\alpha$ -IN-5 intercalates into DNA and binds to the DNA minor groove. Topoisomerase II $\alpha$ -IN-5 exhibits better efficacy and less genotoxicity than <a href="#">Etoposide</a> (HY-13629) <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	topoisomerase II alpha																
<b>In Vitro</b>	<p>Topoisomerase II<math>\alpha</math>-IN-5 (compound 6) (5 <math>\mu</math>M, 10 <math>\mu</math>M, and 20 <math>\mu</math>M; 10 d) inhibits colony formation of DU145 cells<sup>[1]</sup>.</p> <p>Topoisomerase II<math>\alpha</math>-IN-5 (1 <math>\mu</math>M and 10 <math>\mu</math>M; 72 h) shows antiproliferative against DU145 cells<sup>[1]</sup>.</p> <p>Topoisomerase II<math>\alpha</math>-IN-5 has cytotoxicity against DU145, HCT15, and T47D cells with IC<sub>50</sub>s of 0.13 <math>\mu</math>M, 9.25 <math>\mu</math>M, and 0.53 <math>\mu</math>M, respectively<sup>[1]</sup>.</p> <p>Topoisomerase II<math>\alpha</math>-IN-5 (200 <math>\mu</math>M) interacts with a DNA double helix<sup>[1]</sup>.</p> <p>Topoisomerase II<math>\alpha</math>-IN-5 (20 <math>\mu</math>M; 24 h) induces G2 cell cycle arrest and apoptosis in CRPC cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>CRPC cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, and 20 <math>\mu</math>M</td> </tr> <tr> <td>Incubation Time:</td> <td>0, 8, 16, and 24 hours</td> </tr> <tr> <td>Result:</td> <td>Increased the expression of both phosphorylated cdc25c and phosphorylated cdc2.</td> </tr> </table> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>CRPC cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, and 20 <math>\mu</math>M</td> </tr> <tr> <td>Incubation Time:</td> <td>0, 8, 16, and 24 hours</td> </tr> <tr> <td>Result:</td> <td>Induced cell cycle arrest at G2 phase. Induced cell apoptosis.</td> </tr> </table>	Cell Line:	CRPC cells	Concentration:	0, 5, 10, and 20 $\mu$ M	Incubation Time:	0, 8, 16, and 24 hours	Result:	Increased the expression of both phosphorylated cdc25c and phosphorylated cdc2.	Cell Line:	CRPC cells	Concentration:	0, 5, 10, and 20 $\mu$ M	Incubation Time:	0, 8, 16, and 24 hours	Result:	Induced cell cycle arrest at G2 phase. Induced cell apoptosis.
Cell Line:	CRPC cells																
Concentration:	0, 5, 10, and 20 $\mu$ M																
Incubation Time:	0, 8, 16, and 24 hours																
Result:	Increased the expression of both phosphorylated cdc25c and phosphorylated cdc2.																
Cell Line:	CRPC cells																
Concentration:	0, 5, 10, and 20 $\mu$ M																
Incubation Time:	0, 8, 16, and 24 hours																
Result:	Induced cell cycle arrest at G2 phase. Induced cell apoptosis.																

---

## REFERENCES

---

[1]. Jeon KH, et al. Synthesis and evaluation of 7-(3-aminopropoxy)-substituted flavone analogue as a topoisomerase II $\alpha$  catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells. Eur J Med Chem. 2023 Jan 15;246:114999.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA